BioSpace News Archive

Renowned HR Executive Will Focus on Recruiting Top-Tier Talent & Enhancing Workplace Culture

In the wake of CBD’s explosion in the beauty and wellness space as the defining trend of 2019, direct-to-consumer CBD brand Populum announces the launch of Full-Spectrum Hemp CBD Capsules, their latest approachable and no-frills addition to their growing product lineup.

Fresenius Kabi announced today the immediate availability in the United States of Adenosine Injection, USP in 6 mg per 2 mL and 12 mg per 4 mL single dose in Simplist® ready-to-administer prefilled syringes.

At the request of the Investment Industry Regulatory Organization of Canada (IIROC), SLANG Worldwide Inc. (CNSX: SLNG), (Frankfurt: 84S), (“SLANG” or the “Company”), wishes to confirm that the Company’s management is unaware of any material change in the Company’s operations that would account for the recent increase in market activity.

- Wolverine Human Services (WHS), Michigan’s largest child welfare agency, has partnered with Salesforce to create Noble Child, the first cloud-based IT system to meet the data tracking needs of the entire child welfare industry.

EMD Serono, Inc. today announced that Express Scripts is covering on its formulary the oral multiple sclerosis (MS) therapy, MAVENCLAD® (cladribine) tablets, which was approved by the U.S. Food and Drug Administration (FDA) on March 29, 2019.

SmithRx, a San Francisco based technology company and Pharmacy Benefit Manager (PBM), today released the company’s public comment on the HHS proposed rule to end manufacturer-to-PBM rebates in Medicare and Medicaid which have been aided by a safe-harbor protection exempting these rebate payments from federal rules prohibiting kickbacks.

Concert Pharmaceuticals, Inc. announced that the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office has issued a final written decision in connection with the inter partes review of U.S. Patent No. 9,249,149.

Television host, actor, and best-selling author Mario Lopez is supporting veterans by hosting the Wounded Warrior Project® Courage Awards & Benefit Dinner®.

Sangamo Therapeutics, Inc. announced the completion of its previously announced underwritten public offering of 12,650,000 shares of its common stock at a price to the public of $11.50 per share, including 1,650,000 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares.